The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
A Review of the Important Role of CYP2D6 in Pharmacogenomics
Open accessAbstract
Cytochrome P450 2D6 (CYP2D6) is a critical pharmacogene involved in the metabolism of ~20% of commonly used drugs across a broad spectrum of medical disciplines including psychiatry, pain management, oncology and cardiology. Nevertheless, CYP2D6 is highly polymorphic with single-nucleotide polymorphisms, small insertions/deletions and larger structural variants including multiplications, deletions, tandem arrangements, and hybridisations with non-functional CYP2D7 pseudogenes. The frequency of these variants differs across populations, and they significantly influence the drug-metabolising enzymatic function of CYP2D6. Importantly, altered CYP2D6 function has been associated with both adverse drug reactions and reduced drug efficacy, and there is growing recognition of the clinical and economic burdens associated with suboptimal drug utilisation. To date, pharmacogenomic clinical guidelines for at least 48 CYP2D6-substrate drugs have been developed by prominent pharmacogenomics societies, which contain therapeutic recommendations based on CYP2D6-predicted categories of metaboliser phenotype. Novel algorithms to interpret CYP2D6 function from sequencing data that consider structural variants, and machine learning approaches to characterise the functional impact of novel variants, are being developed. However, CYP2D6 genotyping is yet to be implemented broadly into clinical practice, and so further effort and initiatives are required to overcome the implementation challenges and deliver the potential benefits to the bedside.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169 · cited 4×
“The human genome encodes 57 putatively functional CYP genes along with 58 pseudogenes [4].”
BackgroundInfluentialAdverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230
Self-citationPOLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
Cytochromes P450: a success story.
Werck‐Reichhart, D., & Feyereisen, R. (2000) · Genome biology · doi:10.1186/gb-2000-1-6-reviews3003 · Cited by 1,004
Hicks, J., Bishop, Jr., Sangkuhl, K., Müller, D., Ji, Y., Leckband, S., Leeder, J., Graham, R., Chiulli, D., LLerena, A., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.147 · Cited by 998
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Structure and function of cytochromes P450: a comparative analysis of three crystal structures
Hasemann, C. A., Kurumbail, R. G., Boddupalli, S. S., Peterson, J. A., & Deisenhofer, J. (1995) · Structure · doi:10.1016/s0969-2126(01)00134-4 · Cited by 692
Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes
Davies, E. C., Green, C. F., Taylor, S., Williamson, P. R., Mottram, D. R., & Pirmohamed, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004439 · Cited by 692
Self-citationHicks, J., Sangkuhl, K., Swen, J., Ellingrod, V., Müller, D., Shimoda, K., Bishop, Jr., Kharasch, E., Skaar, T., Gaedigk, A., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.597 · Cited by 685
Clinical application of pharmacogenetics
Spear, B. B., Heath-Chiozzi, M., & Huff, J. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)01986-4 · Cited by 646
Zhou, Y., Ingelman‐Sundberg, M., & Lauschke, V. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.690 · Cited by 583
Caudle, K. E., Sangkuhl, K., Whirl‐Carrillo, M., Swen, J. J., Haidar, C. E., Klein, T. E., Gammal, R. S., Relling, M. V., Scott, S. A., Hertz, D. L., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12692 · Cited by 536
Prediction of CYP2D6 phenotype from genotype across world populations
Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T., & Leeder, J. S. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.80 · Cited by 506
Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies
Bouvy, J. C., De Bruin, M. L., & Koopmanschap, M. A. (2015) · Drug Safety · doi:10.1007/s40264-015-0281-0 · Cited by 466
Hicks, J. K., Swen, J. J., Thorn, C. F., Sangkuhl, K., Kharasch, E. D., Ellingrod, V. L., Skaar, T. C., Müller, D. J., Gaedigk, A., & Stingl, J. C. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.2 · Cited by 453
Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR
Tolson, A. H., & Wang, H. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.006 · Cited by 386
Regan, M. M., Leyland-Jones, B., Bouzyk, M., Pagani, O., Tang, W., Kammler, R., Dell’Orto, P., Biasi, M. O., Thürlimann, B., Lyng, M. B., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs125 · Cited by 339
Goetz, M. P., Sangkuhl, K., Guchelaar, H., Schwab, M., Province, M., Whirl‐Carrillo, M., Symmans, W. F., McLeod, H. L., Ratain, M. J., Zembutsu, H., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1007 · Cited by 336
Caudle, K. E., Thorn, C. F., Klein, T. E., Swen, J. J., McLeod, H. L., Diasio, R. B., & Schwab, M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.172 · Cited by 330
van der Wouden, C., Cambon‐Thomsen, A., Cecchin, E., Cheung, K., Dávila‐Fajardo, C., Deneer, V., Dolžan, V, Ingelman‐Sundberg, M., Jönsson, S., Karlsson, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.602 · Cited by 306
Self-citationAddressing phenoconversion: the Achilles' heel of personalized medicine
Shah, R. R., & Smith, R. L. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12441 · Cited by 278
Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver
Yang, X., Zhang, B., Molony, C., Chudin, E., Hao, K., Zhu, J., Gaedigk, A., Suver, C., Zhong, H., Leeder, J. S., et al. (2010) · Genome Research · doi:10.1101/gr.103341.109 · Cited by 271
Lim, H.-S., Ju Lee, H., Seok Lee, K., Sook Lee, E., Jang, I.-J., & Ro, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.4850 · Cited by 268
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
Rae, J. M., Drury, S., Hayes, D. F., Stearns, V., Thibert, J. N., Haynes, B. P., Salter, J., Sestak, I., Cuzick, J., & Dowsett, M. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs126 · Cited by 259
Nofziger, C., Turner, A. J., Sangkuhl, K., Whirl‐Carrillo, M., Agúndez, J. A. G., Black, J. L., Dunnenberger, H. M., Ruano, G., Kennedy, M. A., Phillips, M. S., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1643 · Cited by 242
Bank, P., Caudle, K., Swen, J., Gammal, R., Whirl‐Carrillo, M., Klein, T., Relling, M., & Guchelaar, H. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.762 · Cited by 238
Desta, Z., El‐Boraie, A., Gong, L., Somogyi, A. A., Lauschke, V. M., Dandara, C., Klein, K., Miller, N. A., Klein, T. E., Tyndale, R. F., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2166 · Cited by 234
Complexities of CYP2D6 gene analysis and interpretation
Gaedigk, A. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.825581 · Cited by 224
Rodrigues, M. C. S., & Oliveira, C. D. (2016) · Revista Latino-Americana de Enfermagem · doi:10.1590/1518-8345.1316.2800 · Cited by 218
Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response
Goetz, M. P., Kamal, A., & Ames, M. M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100367 · Cited by 193
Šrejber, M., Navrátilová, V., Paloncýová, M., Bazgier, V., Berka, K., Anzenbacher, P., & Otyepka, M. (2018) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2018.03.002 · Cited by 190
Wang, B., Yang, L.-P., Zhang, X.-Z., Huang, S.-Q., Bartlam, M., & Zhou, S.-F. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530903118729 · Cited by 188
Dutheil, F., Dauchy, S., Diry, M., Sazdovitch, V., Cloarec, O., Mellottée, L., Bièche, I., Ingelman-Sundberg, M., Flinois, J.-P., de Waziers, I., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027011 · Cited by 181
Nebert, D. W., Zhang, G., & Vesell, E. S. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530801952864 · Cited by 181
Mignat, C., Wille, U., & Ziegler, A. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00010-4 · Cited by 179
Werck‐Reichhart, D., Bak, S., & Paquette, S. M. (2002) · The Arabidopsis Book · doi:10.1199/tab.0028 · Cited by 172
Gaedigk, A., Dinh, J., Jeong, H., Prasad, B., & Leeder, J. S. (2018) · Journal of Personalized Medicine · doi:10.3390/jpm8020015 · Cited by 167
Pyrosequencing as a tool for better understanding of human microbiomes
Siqueira, J. F., Fouad, A. F., & Rôças, I. N. (2012) · Journal of Oral Microbiology · doi:10.3402/jom.v4i0.10743 · Cited by 163
Mol*: Towards a Common Library and Tools for Web Molecular Graphics
Sehnal, D., Rose, A., Koča, J., Burley, S. K., & Velankar, S. S. (2018) · Eurographics · doi:10.2312/molva.20181103 · Cited by 158
Munro, A. W., & LINDSAY, J. G. (1996) · Molecular Microbiology · doi:10.1111/j.1365-2958.1996.tb02632.x · Cited by 144
Lee, S., Wheeler, M. M., Patterson, K., McGee, S. R., Dalton, R., Woodahl, E. L., Gaedigk, A., Thummel, K. E., & Nickerson, D. A. (2018) · Genetics in Medicine · doi:10.1038/s41436-018-0054-0 · Cited by 144
Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe
Petrović, J., Pešić, V., & Lauschke, V. M. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-019-0480-8 · Cited by 140
What common structural features and variations of mammalian P450s are known to date?
Otyepka, M., Skopalík, J., Anzenbacherová, E., & Anzenbacher, P. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.09.013 · Cited by 134
Twist, G. P., Gaedigk, A., Miller, N., Farrow, E., Willig, L. K., Dinwiddie, D. L., Petrikin, J. E., Soden, S. E., Herd, S. M., Gibson, M., et al. (2016) · npj Genomic Medicine · doi:10.1038/npjgenmed.2015.7 · Cited by 132
Frequency of CYP2D6 Alleles Including Structural Variants in the United States
Tredici, A. L. D., Malhotra, A., Dedek, M., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00305 · Cited by 125
Sequencing the CYP2D6 Gene: From Variant Allele Discovery to Clinical Pharmacogenetic Testing
Yang, Y., Botton, M. R., Scott, E. R., & Scott, S. A. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0033 · Cited by 124
Fleeman, N., Dundar, Y., Dickson, R., Jorgensen, A., Pushpakom, S. P., McLeod, C., Pirmohamed, M., & Walley, T. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.73 · Cited by 121
Self-citationSuiter, C. C., Moriyama, T., Matreyek, K. A., Yang, W., Scaletti, E. R., Nishii, R., Yang, W., Hoshitsuki, K., Singh, M., Trehan, A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1915680117 · Cited by 121
Evidence for Polymorphism in the Canine Metabolism of the Cyclooxygenase 2 Inhibitor, Celecoxib
Paulson, S. K., Engel, L., Reitz, B. A., Bolten, S., Burton, E. G., Maziasz, T. J., Yan, B., & Schoenhard, G. L. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15037-4 · Cited by 119
Klein, D. J., Thorn, C. F., Desta, Z., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283656bc1 · Cited by 117
Fleischer, S., Sharkey, M., Mealey, K. L., Ostrander, E. A., & Martinez, M. N. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9011-1 · Cited by 110
Finite-time synchronization of coupled neural networks via discontinuous controllers
Shen, J., & Cao, J. (2011) · Cognitive Neurodynamics · doi:10.1007/s11571-011-9163-z · Cited by 103
Canine Cytochrome P-450 Pharmacogenetics
Court, M. H. (2013) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2013.05.001 · Cited by 100
Bank, P. C., Swen, J. J., & Guchelaar, H. (2019) · BMC Medicine · doi:10.1186/s12916-019-1342-5 · Cited by 95
Pharmacogenetics: a general review on progress to date
Daly, A. K. (2017) · British Medical Bulletin · doi:10.1093/bmb/ldx035 · Cited by 92
The endogenous substrates of brain CYP2D
Wang, X., Li, J., Dong, G., & Yue, J. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.12.025 · Cited by 82
Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data
van der Lee, M., Allard, W. G., Vossen, R. H. A. M., Baak-Pablo, R. F., Menafra, R., Deiman, B. A. L. M., Deenen, M. J., Neven, P., Johansson, I., Gastaldello, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf3637 · Cited by 81
Lauschke, V. M., & Ingelman‐Sundberg, M. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-0119-2 · Cited by 79
Metabolism of Sesamin by Cytochrome P450 in Human Liver Microsomes
Yasuda, K., Ikushiro, S., Kamakura, M., Ohta, M., & Sakaki, T. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035659 · Cited by 72
Transcriptional Regulation of CYP2D6 Expression
Pan, X., Ning, M., & Jeong, H. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.072249 · Cited by 71
Bousman, C., Jaksa, P., & Pantelis, C. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000303 · Cited by 71
Funae, Y., Kishimoto, W., Cho, T., Niwa, T., & Hiroi, T. (2003) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.18.337 · Cited by 70
Cardiovascular Pharmacogenomics: Expectations and Practical Benefits
Turner, R. M., & Pirmohamed, M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.234 · Cited by 63
Self-citationGaedigk, A., Fuhr, U., Johnson, C., Bérard, A., Bradford, L. D., & Leeder, J. S. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.133 · Cited by 60
Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry
Jarvis, J. P., Peter, A. P., & Shaman, J. A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00432 · Cited by 59
Koh, K. H., Pan, X., Shen, H.-W., Arnold, S. L. M., Yu, A., Gonzalez, F. J., Isoherranen, N., & Jeong, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.526798 · Cited by 58
Daly, A. K., Idle, J. R., Fairbrother, K. S., Andreassen, O. A., London, S. J., & Steen, V. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199608000-00005 · Cited by 58
Transfer learning enables prediction of CYP2D6 haplotype function
McInnes, G., Dalton, R., Sangkuhl, K., Whirl‐Carrillo, M., Lee, S., Tsao, P. S., Gaedigk, A., Altman, R. B., & Woodahl, E. L. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008399 · Cited by 56
Liau, Y., Maggo, S. D. S., Miller, A. L., Pearson, J. F., Kennedy, M. A., & Cree, S. L. (2019) · Pharmacogenomics · doi:10.2217/pgs-2019-0080 · Cited by 55
de Dueñas, E. M., Aranda, E. O., Blancas, I., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.02.008 · Cited by 53
Frequency of Undetected CYP2D6 Hybrid Genes in Clinical Samples: Impact on Phenotype Prediction
Black, J. L., Walker, D. L., O’Kane, D. J., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040832 · Cited by 49
Kawashima, A., & Satta, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100059 · Cited by 48
Tay-Sontheimer, J., Shireman, L. M., Beyer, R. P., Senn, T. D., Witten, D., Pearce, R. E., Gaedigk, A., Fomban, C. L. G., Lutz, J. D., Isoherranen, N., et al. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.155 · Cited by 47
Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
Chan, C. W. H., Law, B. M. H., So, W. K. W., Chow, K. M., & Waye, M. M. Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03206-w · Cited by 47
Gopisankar, M. G. (2017) · Egyptian Journal of Medical Human Genetics · doi:10.1016/j.ejmhg.2017.03.001 · Cited by 46
Ramamoorthy, A., Flockhart, D. A., Hosono, N., Kubo, M., Nakamura, Y., & Skaar, T. C. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833a1083 · Cited by 41
Effect of health foods on cytochrome P450-mediated drug metabolism
Sasaki, T., Sato, Y., Kumagai, T., et al. (2017) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-017-0083-x · Cited by 40
Parveen, F., Faridi, R. M., Das, V., Tripathi, G., & Agrawal, S. (2009) · Molecular Human Reproduction · doi:10.1093/molehr/gap096 · Cited by 38
Zhang, H.-F., Li, Z.-H., Liu, J.-Y., Liu, T.-T., Wang, P., Fang, Y., Zhou, J., Cui, M.-Z., Gao, N., Tian, X., et al. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.069849 · Cited by 38
Koh, K. H., Pan, X., Zhang, W., McLachlan, A., Urrutia, R. A., & Jeong, H. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.093666 · Cited by 36
Ferner, R. E., & McGettigan, P. (2018) · BMJ · doi:10.1136/bmj.k4051 · Cited by 35
Kiyotani, K., Shimizu, M., Kumai, T., et al. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0876-4 · Cited by 31
CYP2D6allele frequencies, copy number variants, and tandems in the population of Hong Kong
Chan, W., Li, M. S., Sundaram, S. K., et al. (2018) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22634 · Cited by 31
Hosein, A. N., Song, S., Reed, A. E. M., Jayanthan, J., Reid, L., Kutasovic, J. R., Cummings, M. C., Waddell, N., Lakhani, S. R., Chenevix‐Trench, G., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.54 · Cited by 30
Puaprasert, K., Chu, C. S., Saralamba, N., Day, N. P. J., Nosten, F. H., White, N. J., Dondorp, A. M., & Imwong, M. (2018) · Malaria Journal · doi:10.1186/s12936-018-2579-8 · Cited by 26
New insights into the role of cytochrome P450 reductase (POR) in microsomal redox biology
Porter, T. D. (2012) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2012.02.002 · Cited by 24
Campion, D. P., & Dowell, F. J. (2019) · Frontiers in Veterinary Science · doi:10.3389/fvets.2019.00022 · Cited by 21
Copy number variation profiling in pharmacogenetics CYP-450 and GST genes in Colombian population
Ramírez, B., Niño-Orrego, M. J., Cárdenas, D., Ariza, K. E., Quintero, K., Bravo, N. C. C., Tamayo-Agudelo, C., González, M. A., Laissue, P., & Fonseca, D. J. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0556-x · Cited by 20
Wei, X., Sun, H., Zhuang, J., Weng, X., Zheng, B., Lin, Q., Zhang, G., & Cai, J. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00842-0 · Cited by 13
Predicting CYP2D6 phenotype from resting brain perfusion images by gradient boosting
Napolitano, G., Stingl, J., Schmid, M. C., & Viviani, R. (2016) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2016.11.005 · Cited by 11
Suiter, C. C., Moriyama, T., Matreyek, K. A., Yang, W., Scaletti, E. R., Nishii, R., Yang, W., Hoshitsuki, K., Singh, M., Trehan, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/740837 · Cited by 2
Cited by
Pharmacological Treatment of Obesity in Older Adults
Žižka, O., Haluzík, M., & Jude, E. B. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01150-9 · Cited by 23
Evaluation of PE5 Entries on the Human Proteome Project Target List
Zheng, C., Andken, M., Mudge, J. M., Magrane, M., Orchard, S., Sun, Z., & Deutsch, E. W. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00167 · Cited by 1
Metadata
- Authors
- Taylor, C., Crosby, I., Yip, V., Maguire, P., Pirmohamed, M., & Turner, R. M.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2020-10-30
- Volume
- 11
- Issue
- 11
- Pages
- 1295
- ISSN
- 2073-4425 (ISSN-L)
- OpenAlex
- W3096673836
- Cited by
- 316
- References
- 91
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.